File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: KRAS Mutation Testing on Endoscopic Ultrasound-Guided Fine-Needle Aspiration Samples Improves the Diagnostic Accuracy of Pancreatic Cancer

TitleKRAS Mutation Testing on Endoscopic Ultrasound-Guided Fine-Needle Aspiration Samples Improves the Diagnostic Accuracy of Pancreatic Cancer
Authors
Keywordsdiagnostic sensitivity
EUS-FNA
KRAS mutation
pancreatic mass
Issue Date1-Nov-2022
PublisherLippincott, Williams & Wilkins
Citation
Pancreas, 2022, v. 51, n. 10, p. 1365-1371 How to Cite?
Abstract

Objectives 

Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) cytology was one of the investigations for pancreatic masses. While the specificity approached 100%, its sensitivity remained low because of high rate of indeterminate and false-negative results. Meanwhile, KRAS gene was frequently mutated in up to 90% of pancreatic ductal adenocarcinoma and its precursor lesions. This study aimed to determine whether KRAS mutation analysis could improve the diagnostic sensitivity in EUS-FNA samples for pancreatic adenocarcinoma.

Methods 

The EUS-FNA samples from patients with a pancreatic mass obtained between January 2016 and December 2017 were reviewed retrospectively. The cytology results were classified as malignant, suspicious for malignancy, atypical, negative for malignancy, and nondiagnostic. KRAS mutation testing was performed using polymerase chain reaction followed by Sanger sequencing.

Results 

A total of 126 EUS-FNA specimens were reviewed. The overall sensitivity and specificity by cytology alone were 29% and 100%, respectively. When KRAS mutation testing was performed in cases with indeterminate and negative cytology, the sensitivity increased to 74.2%, and the specificity remained at 100%.

Conclusions 

KRAS mutation analysis, especially when performed in cytologically indeterminate cases, improves the diagnostic accuracy for pancreatic ductal adenocarcinoma. This may reduce the need to repeat invasive EUS-FNA for diagnosis.


Persistent Identifierhttp://hdl.handle.net/10722/340801
ISSN
2023 Impact Factor: 1.7
2023 SCImago Journal Rankings: 0.764
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYeung, MCF-
dc.contributor.authorShek, TWH-
dc.date.accessioned2024-03-11T10:47:20Z-
dc.date.available2024-03-11T10:47:20Z-
dc.date.issued2022-11-01-
dc.identifier.citationPancreas, 2022, v. 51, n. 10, p. 1365-1371-
dc.identifier.issn0885-3177-
dc.identifier.urihttp://hdl.handle.net/10722/340801-
dc.description.abstract<h3>Objectives </h3><p>Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) cytology was one of the investigations for pancreatic masses. While the specificity approached 100%, its sensitivity remained low because of high rate of indeterminate and false-negative results. Meanwhile, <em>KRAS</em> gene was frequently mutated in up to 90% of pancreatic ductal adenocarcinoma and its precursor lesions. This study aimed to determine whether <em>KRAS</em> mutation analysis could improve the diagnostic sensitivity in EUS-FNA samples for pancreatic adenocarcinoma.</p><h3>Methods </h3><p>The EUS-FNA samples from patients with a pancreatic mass obtained between January 2016 and December 2017 were reviewed retrospectively. The cytology results were classified as malignant, suspicious for malignancy, atypical, negative for malignancy, and nondiagnostic. <em>KRAS</em> mutation testing was performed using polymerase chain reaction followed by Sanger sequencing.</p><h3>Results </h3><p>A total of 126 EUS-FNA specimens were reviewed. The overall sensitivity and specificity by cytology alone were 29% and 100%, respectively. When <em>KRAS</em> mutation testing was performed in cases with indeterminate and negative cytology, the sensitivity increased to 74.2%, and the specificity remained at 100%.</p><h3>Conclusions </h3><p><em>KRAS</em> mutation analysis, especially when performed in cytologically indeterminate cases, improves the diagnostic accuracy for pancreatic ductal adenocarcinoma. This may reduce the need to repeat invasive EUS-FNA for diagnosis.</p>-
dc.languageeng-
dc.publisherLippincott, Williams & Wilkins-
dc.relation.ispartofPancreas-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectdiagnostic sensitivity-
dc.subjectEUS-FNA-
dc.subjectKRAS mutation-
dc.subjectpancreatic mass-
dc.titleKRAS Mutation Testing on Endoscopic Ultrasound-Guided Fine-Needle Aspiration Samples Improves the Diagnostic Accuracy of Pancreatic Cancer-
dc.typeArticle-
dc.identifier.doi10.1097/MPA.0000000000002193-
dc.identifier.pmid37099780-
dc.identifier.scopuseid_2-s2.0-85153923038-
dc.identifier.volume51-
dc.identifier.issue10-
dc.identifier.spage1365-
dc.identifier.epage1371-
dc.identifier.eissn1536-4828-
dc.identifier.isiWOS:000979053600022-
dc.publisher.placePHILADELPHIA-
dc.identifier.issnl0885-3177-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats